Review



cis  (Gerstel GmbH)


Bioz Verified Symbol Gerstel GmbH is a verified supplier
Bioz Manufacturer Symbol Gerstel GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    Gerstel GmbH cis
    Cis, supplied by Gerstel GmbH, used in various techniques. Bioz Stars score: 97/100, based on 2389 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/CIS/custom%40cis%4042219630
    Average 97 stars, based on 2389 article reviews
    cis - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    Gas Chromatography-Mass Spectrometry:

    Article Title: Comparative Characterisation of the Volatile and Sensory Profiles of a Dealcoholised White Wine (Airen) Produced by Different Membrane and Thermal-Based Technologies
    Article Snippet: .. The GC-MS used was a GC 7890 A, equipped with an MS 5975 B (both Agilent, Santa Clara, CA, USA), an MPS robotic autosampler and a CIS 4 (both Gerstel, Mülheim an der Ruhr, Germany). .. A 65 μm fibre coated with polydimethylsiloxane crosslinked with divinylbenzene (Supelco, Merck, Darmstadt, Germany) was used to carry out the solid-phase microextraction.

    Gas Chromatography:

    Article Title: Comparative Characterisation of the Volatile and Sensory Profiles of a Dealcoholised White Wine (Airen) Produced by Different Membrane and Thermal-Based Technologies
    Article Snippet: .. The GC-MS used was a GC 7890 A, equipped with an MS 5975 B (both Agilent, Santa Clara, CA, USA), an MPS robotic autosampler and a CIS 4 (both Gerstel, Mülheim an der Ruhr, Germany). .. A 65 μm fibre coated with polydimethylsiloxane crosslinked with divinylbenzene (Supelco, Merck, Darmstadt, Germany) was used to carry out the solid-phase microextraction.

    Article Title: Discovering Vitis Vinifera (L.) Biodiversity: Berry Quality Traits of Four Unexploited Table Grape Genotypes
    Article Snippet: The stir bar was transferred into a thermal desorption unit (TDU, Gerstel, Mulheim and der Ruhr, Germany) and volatiles were desorbed in the splitless mode. .. Desorbed analytes were cryo-focused at 0°C using liquid CO2, in a programmed temperature vaporization injector (CIS 4, Gerstel, Mulheim and der Ruhr, Germany); the cryo-focalized analytes were transferred to the GC column by ramping at 12 °C/s until 300°C (held for 6.00 min). ..

    Article Title: Identification of aversive aroma compounds that limit consumer acceptance of pea protein isolates using an integrated flavoromics approach
    Article Snippet: Pea protein isolates (PPIs) have emerged as sustainable plant-based protein ingredients; however, their widespread utilization remains constrained by undesirable off-flavors that limit consumer acceptance.. This study aimed to identify the volatile compounds responsible for consumer disliking of commercial PPIs using an integrated flavoromics approach.. A total of 39 aroma compounds were identified in an equal-proportion blend of 12 commercial PPI samples by gas chromatography–mass spectrometry/olfactometry.

    Mass Spectrometry:

    Article Title: Comparative Characterisation of the Volatile and Sensory Profiles of a Dealcoholised White Wine (Airen) Produced by Different Membrane and Thermal-Based Technologies
    Article Snippet: .. The GC-MS used was a GC 7890 A, equipped with an MS 5975 B (both Agilent, Santa Clara, CA, USA), an MPS robotic autosampler and a CIS 4 (both Gerstel, Mülheim an der Ruhr, Germany). .. A 65 μm fibre coated with polydimethylsiloxane crosslinked with divinylbenzene (Supelco, Merck, Darmstadt, Germany) was used to carry out the solid-phase microextraction.

    Article Title: Identification of aversive aroma compounds that limit consumer acceptance of pea protein isolates using an integrated flavoromics approach
    Article Snippet: Pea protein isolates (PPIs) have emerged as sustainable plant-based protein ingredients; however, their widespread utilization remains constrained by undesirable off-flavors that limit consumer acceptance.. This study aimed to identify the volatile compounds responsible for consumer disliking of commercial PPIs using an integrated flavoromics approach.. A total of 39 aroma compounds were identified in an equal-proportion blend of 12 commercial PPI samples by gas chromatography–mass spectrometry/olfactometry.

    Robotic:

    Article Title: Comparative Characterisation of the Volatile and Sensory Profiles of a Dealcoholised White Wine (Airen) Produced by Different Membrane and Thermal-Based Technologies
    Article Snippet: .. The GC-MS used was a GC 7890 A, equipped with an MS 5975 B (both Agilent, Santa Clara, CA, USA), an MPS robotic autosampler and a CIS 4 (both Gerstel, Mülheim an der Ruhr, Germany). .. A 65 μm fibre coated with polydimethylsiloxane crosslinked with divinylbenzene (Supelco, Merck, Darmstadt, Germany) was used to carry out the solid-phase microextraction.

    Targeted Proteomics:

    Article Title: Identification of aversive aroma compounds that limit consumer acceptance of pea protein isolates using an integrated flavoromics approach
    Article Snippet: Pea protein isolates (PPIs) have emerged as sustainable plant-based protein ingredients; however, their widespread utilization remains constrained by undesirable off-flavors that limit consumer acceptance.. This study aimed to identify the volatile compounds responsible for consumer disliking of commercial PPIs using an integrated flavoromics approach.. A total of 39 aroma compounds were identified in an equal-proportion blend of 12 commercial PPI samples by gas chromatography–mass spectrometry/olfactometry.

    Dynamic Headspace:

    Article Title: Identification of aversive aroma compounds that limit consumer acceptance of pea protein isolates using an integrated flavoromics approach
    Article Snippet: Pea protein isolates (PPIs) have emerged as sustainable plant-based protein ingredients; however, their widespread utilization remains constrained by undesirable off-flavors that limit consumer acceptance.. This study aimed to identify the volatile compounds responsible for consumer disliking of commercial PPIs using an integrated flavoromics approach.. A total of 39 aroma compounds were identified in an equal-proportion blend of 12 commercial PPI samples by gas chromatography–mass spectrometry/olfactometry.

    Thermal Desorption:

    Article Title: Identification of aversive aroma compounds that limit consumer acceptance of pea protein isolates using an integrated flavoromics approach
    Article Snippet: Pea protein isolates (PPIs) have emerged as sustainable plant-based protein ingredients; however, their widespread utilization remains constrained by undesirable off-flavors that limit consumer acceptance.. This study aimed to identify the volatile compounds responsible for consumer disliking of commercial PPIs using an integrated flavoromics approach.. A total of 39 aroma compounds were identified in an equal-proportion blend of 12 commercial PPI samples by gas chromatography–mass spectrometry/olfactometry.



    Similar Products

    94
    MedChemExpress cis 3 hexen 1 ol
    Cis 3 Hexen 1 Ol, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/cis-3-Hexen-1-ol/pm42993376-42-8-10
    Average 94 stars, based on 1 article reviews
    cis 3 hexen 1 ol - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    97
    Gerstel GmbH cis
    Cis, supplied by Gerstel GmbH, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/CIS/custom%40cis%4042899634
    Average 97 stars, based on 1 article reviews
    cis - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    96
    Nikon eclipse ci pol polarizing microscope
    Eclipse Ci Pol Polarizing Microscope, supplied by Nikon, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/ECLIPSE+Ci-POL/pmc13750947-75-17-16
    Average 96 stars, based on 1 article reviews
    eclipse ci pol polarizing microscope - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    OriGene mouse cish
    Mouse Cish, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/Cish+Mouse+qPCR+Primer+Pair/pm42995494-185-64-66
    Average 94 stars, based on 1 article reviews
    mouse cish - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc igf 2
    Igf 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/IGF-II+Receptor%2FCI-M6PR+Rabbit+mAb/10__1158_slash_2767___9764__crc___26___0581-90-4-5
    Average 94 stars, based on 1 article reviews
    igf 2 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Novus Biologicals f4 80
    F4 80, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/F4%2F80+Antibody+(CI%3AA3-1)/10__12746_slash_swjm__v14i61__1703-97-24-25
    Average 94 stars, based on 1 article reviews
    f4 80 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Plasmidsaurus ci operon
    Ci Operon, supplied by Plasmidsaurus, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/ZeroPrep+Colony+Sequencing/bio_rxiv__64898__2026__10__08__757549-119-2-26
    Average 95 stars, based on 1 article reviews
    ci operon - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    99
    MedChemExpress cis diamminedichloroplatinum ddp
    Cis Diamminedichloroplatinum Ddp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/Cisplatin/pm42853628-42-7-10
    Average 99 stars, based on 1 article reviews
    cis diamminedichloroplatinum ddp - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology 9 cis retinoic acid
    Evaluation of the drug combinations for anti-proliferative effects on different CRC cell lines. The response of drug combinations was further evaluated for antagonistic, additive, and synergistic responses on CRC cell proliferation. The combination effects were calculated as a ratio of the observed response divided by the predicted response based on the Bliss independence model. <xref ref-type= 52 Panel A shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have additive effects in HT29 cells. Panel B shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have synergistic effects in HCT116 cells. Panel C shows that Talarozole + Sulindac have synergistic effects in SW480 cells. The synergistic response is < 1, additive ~1, and antagonistic > 1. " width="250" height="auto" />
    9 Cis Retinoic Acid, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/9-cis-Retinoic+acid/pmc13652067-69-13-16
    Average 93 stars, based on 1 article reviews
    9 cis retinoic acid - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    90
    Larodan cis 2 hexadecenoic acids
    Evaluation of the drug combinations for anti-proliferative effects on different CRC cell lines. The response of drug combinations was further evaluated for antagonistic, additive, and synergistic responses on CRC cell proliferation. The combination effects were calculated as a ratio of the observed response divided by the predicted response based on the Bliss independence model. <xref ref-type= 52 Panel A shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have additive effects in HT29 cells. Panel B shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have synergistic effects in HCT116 cells. Panel C shows that Talarozole + Sulindac have synergistic effects in SW480 cells. The synergistic response is < 1, additive ~1, and antagonistic > 1. " width="250" height="auto" />
    Cis 2 Hexadecenoic Acids, supplied by Larodan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cis/2(Z)-Hexadecenoic+acid/pm42847705-204-2-7
    Average 90 stars, based on 1 article reviews
    cis 2 hexadecenoic acids - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Evaluation of the drug combinations for anti-proliferative effects on different CRC cell lines. The response of drug combinations was further evaluated for antagonistic, additive, and synergistic responses on CRC cell proliferation. The combination effects were calculated as a ratio of the observed response divided by the predicted response based on the Bliss independence model. <xref ref-type= 52 Panel A shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have additive effects in HT29 cells. Panel B shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have synergistic effects in HCT116 cells. Panel C shows that Talarozole + Sulindac have synergistic effects in SW480 cells. The synergistic response is < 1, additive ~1, and antagonistic > 1. " width="100%" height="100%">

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Evaluation of the drug combinations for anti-proliferative effects on different CRC cell lines. The response of drug combinations was further evaluated for antagonistic, additive, and synergistic responses on CRC cell proliferation. The combination effects were calculated as a ratio of the observed response divided by the predicted response based on the Bliss independence model. 52 Panel A shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have additive effects in HT29 cells. Panel B shows that 9-cis-RA + Sulindac and Piroxicam, Liarozole + Piroxicam, and ATRA + Sulindac have synergistic effects in HCT116 cells. Panel C shows that Talarozole + Sulindac have synergistic effects in SW480 cells. The synergistic response is < 1, additive ~1, and antagonistic > 1.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques:

    Drug combination effects on stem cells and neuroendocrine cells. The effects of retinoids and anti-WNT agents on ALDH + stem cells were evaluated based on the ALDEFLUOR assay. The results showed that treatment with the 9-cis RA + Sulindac drug combination substantially decreased the population of ALDH + cells in HCT116 cells (Panel B), but not in HT29 (Panel A) or SW480 (Panel C) cells. Notably, this decrease was seen in HCT116 cells at both time points (24 and 48 h). Neuroendocrine cells (NECs). The effects of retinoids and anti-WNT agents on NEC differentiation were evaluated using western blot analysis for expression of differentiation markers in HCT116 CRC cells (Panels D–F) and SW480 cells (Panels G–I). The results show that drug combinations increase NEC differentiation in HCT116 and SW480 CRC cells. GLP2R = glucagon-like protein two receptors, SSTR1 = somatostatin receptor 1, CHGA = chromogranin A, NSE = neuron-specific enolase. The experiments were done in triplicate, and the error bars represent ± the SEM. * p < 0.05.

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Drug combination effects on stem cells and neuroendocrine cells. The effects of retinoids and anti-WNT agents on ALDH + stem cells were evaluated based on the ALDEFLUOR assay. The results showed that treatment with the 9-cis RA + Sulindac drug combination substantially decreased the population of ALDH + cells in HCT116 cells (Panel B), but not in HT29 (Panel A) or SW480 (Panel C) cells. Notably, this decrease was seen in HCT116 cells at both time points (24 and 48 h). Neuroendocrine cells (NECs). The effects of retinoids and anti-WNT agents on NEC differentiation were evaluated using western blot analysis for expression of differentiation markers in HCT116 CRC cells (Panels D–F) and SW480 cells (Panels G–I). The results show that drug combinations increase NEC differentiation in HCT116 and SW480 CRC cells. GLP2R = glucagon-like protein two receptors, SSTR1 = somatostatin receptor 1, CHGA = chromogranin A, NSE = neuron-specific enolase. The experiments were done in triplicate, and the error bars represent ± the SEM. * p < 0.05.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Western Blot, Analysis, Expressing

    The effect of drug combinations on changes in gene expression in CRC cells. We conducted NanoString Profiling of HCT116 and SW480 cells treated with 9-cis-RA and Liarozole in combination with Sulindac to study the effects of drug combinations on gene expression. The heat maps (Panels A & B) show that drug combination treatments involving an RA agent (9-cis RA or Liarozole) in combination with an anti-WNT agent (Sulindac) lead to dramatic differences in gene expression compared to treatment with single agents. Sulindac treatment leads to the downregulation of a substantial number of genes in HCT116 cells (Panel C) and SW480 cells (Panel D). This down-regulation is characterized by changes in the expression of various WNT target genes. Changes in the expression of genes with WNT-regulatory elements (WREs) in HCT116 (Panels A and C) and SW480 (Panels B and D) cells indicate that Sulindac targets WNT signaling. Genes with WNT-regulatory elements show up- or down-regulation of expression (>2X-fold) in response to Sulindac treatment in HCT116 (Panel C) and SW480 (Panel D) CRC cells. In HCT116 cells, decreased expression of the notable WNT target genes MET , MYC , AXIN2 , BMP4 , RNF43 , and TCF3 are shown (Panel E). While in SW480 cells, the expression of the WNT target genes AXIN2 , BMP4 , RNF43 , and CCND1 had decreased (Panel F).

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: The effect of drug combinations on changes in gene expression in CRC cells. We conducted NanoString Profiling of HCT116 and SW480 cells treated with 9-cis-RA and Liarozole in combination with Sulindac to study the effects of drug combinations on gene expression. The heat maps (Panels A & B) show that drug combination treatments involving an RA agent (9-cis RA or Liarozole) in combination with an anti-WNT agent (Sulindac) lead to dramatic differences in gene expression compared to treatment with single agents. Sulindac treatment leads to the downregulation of a substantial number of genes in HCT116 cells (Panel C) and SW480 cells (Panel D). This down-regulation is characterized by changes in the expression of various WNT target genes. Changes in the expression of genes with WNT-regulatory elements (WREs) in HCT116 (Panels A and C) and SW480 (Panels B and D) cells indicate that Sulindac targets WNT signaling. Genes with WNT-regulatory elements show up- or down-regulation of expression (>2X-fold) in response to Sulindac treatment in HCT116 (Panel C) and SW480 (Panel D) CRC cells. In HCT116 cells, decreased expression of the notable WNT target genes MET , MYC , AXIN2 , BMP4 , RNF43 , and TCF3 are shown (Panel E). While in SW480 cells, the expression of the WNT target genes AXIN2 , BMP4 , RNF43 , and CCND1 had decreased (Panel F).

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Gene Expression, Profiling, Expressing

    Analysis of Sulindac’s ability to sensitize CRC cells to the effect of retinoids based on gene expression. Further NanoString expression profiling was done on HCT116 and SW480 cells treated with 9-cis-RA or Liarozole in combination with Sulindac. The effect of RA agents on CRC cells . The Venn diagrams (Panel A) show that changes in the expression ( p < 0.05) of the same genes in both cell lines (HCT116 and SW480) occurred with 9-cis-RA treatment ( n = 38 genes) and Liarozole treatment ( n = 45 genes). The Venn diagrams (Panel B) also show that changes in the expression ( p < 0.05) of the same genes occur with both RA agents (9-cis-RA and Liarozole) in HCT116 ( n = 49 genes) and SW480 cells ( n = 65 genes). These results indicate that a common set of genes is targeted by both of the RA agents (9-cis-RA and Liarozole) in CRC cells. Indeed, 19 of the same genes changed in expression (7 upregulated and 12 down-regulated) with both RA agent treatments and in both CRC cell lines (Panel C). The effect of Sulindac on responses to RA agents . In both HCT116 (Panels D and E) and SW480 (Panels F and G) cells, one set of genes is down-regulated, and another set is up-regulated ( p < 0.05) by retinoid agents after Sulindac treatment. Additional analyses to illustrate the change in the expression of the specific genes are presented in waterfall plots (Figure S3) and in lists of the top 10 genes upregulated (Table S3) and downregulated (Table S4) by RA agents after Sulindac treatment. Interestingly, many of the same genes are upregulated or downregulated by Liarozole and 9-cis RA in both cell lines. Overall, these results indicate that Sulindac sensitizes HCT116 and SW480 CRC cells to the effect of retinoids on gene expression.

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Analysis of Sulindac’s ability to sensitize CRC cells to the effect of retinoids based on gene expression. Further NanoString expression profiling was done on HCT116 and SW480 cells treated with 9-cis-RA or Liarozole in combination with Sulindac. The effect of RA agents on CRC cells . The Venn diagrams (Panel A) show that changes in the expression ( p < 0.05) of the same genes in both cell lines (HCT116 and SW480) occurred with 9-cis-RA treatment ( n = 38 genes) and Liarozole treatment ( n = 45 genes). The Venn diagrams (Panel B) also show that changes in the expression ( p < 0.05) of the same genes occur with both RA agents (9-cis-RA and Liarozole) in HCT116 ( n = 49 genes) and SW480 cells ( n = 65 genes). These results indicate that a common set of genes is targeted by both of the RA agents (9-cis-RA and Liarozole) in CRC cells. Indeed, 19 of the same genes changed in expression (7 upregulated and 12 down-regulated) with both RA agent treatments and in both CRC cell lines (Panel C). The effect of Sulindac on responses to RA agents . In both HCT116 (Panels D and E) and SW480 (Panels F and G) cells, one set of genes is down-regulated, and another set is up-regulated ( p < 0.05) by retinoid agents after Sulindac treatment. Additional analyses to illustrate the change in the expression of the specific genes are presented in waterfall plots (Figure S3) and in lists of the top 10 genes upregulated (Table S3) and downregulated (Table S4) by RA agents after Sulindac treatment. Interestingly, many of the same genes are upregulated or downregulated by Liarozole and 9-cis RA in both cell lines. Overall, these results indicate that Sulindac sensitizes HCT116 and SW480 CRC cells to the effect of retinoids on gene expression.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Analysis, Gene Expression, Expressing, Profiling

    The two sets of retinoid-response genes (down-regulated vs. up-regulated) have different functional classifications. <xref ref-type= * " width="100%" height="100%">

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: The two sets of retinoid-response genes (down-regulated vs. up-regulated) have different functional classifications. *

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Functional Assay, Transduction, Tissue, Cell Differentiation

    Measuring drug responses using organoid cultures of human CRC cells. The effect of therapeutic manipulation of WNT and RA signaling was evaluated in human patient-derived colon cancer organoids. Drug-response experiments were conducted using a CRC organoid model from the ATCC (HCM-CSHL-0257-C18). Treatment concentrations were chosen based on the effective IC50 doses as indicated: 9-cis-RA (90 µM), Sulindac (322.5, 430, 537.5 µM), and Liarozole (90 µM). Panels A & B show representative microscopy staining from cell viability analysis using CYTO 3D Live/Dead Assay Kit. Scale bars equal 50 µM. Each panel contains four rows of images. Brightfield shows the overall cell morphology under normal light. AO (acridine orange): green fluorescence indicating live cells. PI (propidium iodide): red fluorescence marks dead cells. Merged: A combination of AO and PI channels showing both live and dead cells simultaneously.Panels C and D give the quantification for cell death based on the PI (dead cells)/AO (live cells) ratio. The cells were treated with various concentrations of 9-cis-RA, Liarozole, Sulindac alone, or combinations of both compounds. The control represents untreated cells. Increasing ratios indicate higher proportions of dead cells than live cells, with combination treatments showing the most pronounced effects. This experiment was done in triplicate, and the error bars represent ± the SEM. Overall, treating CRC organoid cultures with anti-WNT & RA drug combinations causes a substantial increase in cell death compared to individual agents alone.

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Measuring drug responses using organoid cultures of human CRC cells. The effect of therapeutic manipulation of WNT and RA signaling was evaluated in human patient-derived colon cancer organoids. Drug-response experiments were conducted using a CRC organoid model from the ATCC (HCM-CSHL-0257-C18). Treatment concentrations were chosen based on the effective IC50 doses as indicated: 9-cis-RA (90 µM), Sulindac (322.5, 430, 537.5 µM), and Liarozole (90 µM). Panels A & B show representative microscopy staining from cell viability analysis using CYTO 3D Live/Dead Assay Kit. Scale bars equal 50 µM. Each panel contains four rows of images. Brightfield shows the overall cell morphology under normal light. AO (acridine orange): green fluorescence indicating live cells. PI (propidium iodide): red fluorescence marks dead cells. Merged: A combination of AO and PI channels showing both live and dead cells simultaneously.Panels C and D give the quantification for cell death based on the PI (dead cells)/AO (live cells) ratio. The cells were treated with various concentrations of 9-cis-RA, Liarozole, Sulindac alone, or combinations of both compounds. The control represents untreated cells. Increasing ratios indicate higher proportions of dead cells than live cells, with combination treatments showing the most pronounced effects. This experiment was done in triplicate, and the error bars represent ± the SEM. Overall, treating CRC organoid cultures with anti-WNT & RA drug combinations causes a substantial increase in cell death compared to individual agents alone.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Derivative Assay, Organoids, Microscopy, Staining, Analysis, Live Dead Assay, Brightfield, Morphology, Fluorescence, Control

    Drug combination responses in a human CRC PDX (CTG-2359) mouse model. Drug safety . Drug toxicity was initially evaluated for tolerability (Panel A), and during drug treatments for efficacy. Different colored lines indicate various treatment conditions, including control and combination treatments. Body weights remained mostly stable with no weight loss greater than 10%. This reveals that the drug treatments were reasonably well tolerated. Efficacy analysis . Panel B shows the time course results on tumor volume changes in the efficacy study over 28 d. The treatment groups included a placebo control and various Sulindac, Liarozole, and 9-cis RA combinations. The tumor volumes were measured in cubic millimeters and plotted against time (days). The error bars represent ± the SEM. All the treatment groups showed progressive tumor growth, with the combinations of Sulindac + Liarozole + 9-cis RA demonstrating the lowest tumor volume trajectory. The placebo group exhibited the highest tumor growth rate, reaching approximately 2000 mm 3 by day 25. Measurements were taken at 5-day intervals after treatment initiation at day 0. Panel C. The waterfall plot shows the percent decreased in tumor growth for all treatment groups. The corresponding values for anti-tumor activity are provided in Table 3 below.

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Drug combination responses in a human CRC PDX (CTG-2359) mouse model. Drug safety . Drug toxicity was initially evaluated for tolerability (Panel A), and during drug treatments for efficacy. Different colored lines indicate various treatment conditions, including control and combination treatments. Body weights remained mostly stable with no weight loss greater than 10%. This reveals that the drug treatments were reasonably well tolerated. Efficacy analysis . Panel B shows the time course results on tumor volume changes in the efficacy study over 28 d. The treatment groups included a placebo control and various Sulindac, Liarozole, and 9-cis RA combinations. The tumor volumes were measured in cubic millimeters and plotted against time (days). The error bars represent ± the SEM. All the treatment groups showed progressive tumor growth, with the combinations of Sulindac + Liarozole + 9-cis RA demonstrating the lowest tumor volume trajectory. The placebo group exhibited the highest tumor growth rate, reaching approximately 2000 mm 3 by day 25. Measurements were taken at 5-day intervals after treatment initiation at day 0. Panel C. The waterfall plot shows the percent decreased in tumor growth for all treatment groups. The corresponding values for anti-tumor activity are provided in Table 3 below.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Toxicity, Control, Analysis, Activity Assay

    Anti-tumor activity for human CRC PDX (CTG-2359) mouse model.

    Journal: Cancer Biology & Therapy

    Article Title: Inhibition of WNT signaling sensitizes CRC cells to anti-tumor effects of retinoids: basis for new drug combinations in oncology

    doi: 10.1080/15384047.2026.2732738

    Figure Lengend Snippet: Anti-tumor activity for human CRC PDX (CTG-2359) mouse model.

    Article Snippet: Drug sources are as follows: Sulindac, Piroxicam, and Talarozole (Sigma-Aldrich, St Louis, MO), 9-cis retinoic acid (Santa Cruz Biotechnology, Dallas, TX), Liarozole (R&D Chemical, Gonzales, LA), and all-trans retinoic acid (Stem Cell Technologies, Vancouver, BC).

    Techniques: Activity Assay, Control